Loading clinical trials...

Observational Evaluation of Atopic Dermatitis in Pediatric Patients | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITING

Observational Evaluation of Atopic Dermatitis in Pediatric Patients

Prospective, Observational, Longitudinal Study in Pediatric Patients With Moderate to Severe Atopic Dermatitis Whose Disease is Not Adequately Controlled With Topical Prescription Therapies or When Those Therapies Are Not Medically Advisable

NCT03687359•Sanofi

View on ClinicalTrials.gov

Summary

Primary Objectives: * To describe the characteristics of pediatric patients with moderate to severe atopic dermatitis (AD) whose disease is not adequately controlled with topical therapies or when those therapies are not medically advisable. * To evaluate the time-course of AD and selected atopic comorbidities. Secondary Objectives: * To characterize disease burden and unmet need. * To describe real-world treatment patterns (eg, dosing regimens, treatment duration, and reasons for discontinuation and/or switching). * To document the real-world effectiveness and safety of treatments.

Detailed Description

The study duration is 120 months.

Eligibility

Age

0 - 11 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients with moderate to severe AD, according to the Investigator's assessment;
•Currently receiving systemic treatment (including phototherapy) for atopic dermatitis or currently on topical treatment, but otherwise candidates for systemic treatment.

Exclusion Criteria

•Concurrent participation in an interventional clinical trial which modifies patient care.
•The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Locations (182)

C Squared Research Center- Site Number : 8400068

Birmingham, Alabama, United States

Cahaba Dermatology & Skin Health Center- Site Number : 8400046

Birmingham, Alabama, United States

C2 Research Center, LLC- Site Number : 8400071

Montgomery, Alabama, United States

Phoenix Children's Hospital, Inc.- Site Number : 8400015

Phoenix, Arizona, United States

Orange County Research Institute- Site Number : 8400028

Anaheim, California, United States

Axis Clinical Trials- Site Number : 8400025

Los Angeles, California, United States

Madera Family Medical Group- Site Number : 8400054

Madera, California, United States

Carey Chronis, MD, FAAP- Site Number : 8400033

Ventura, California, United States

Daxia Trials- Site Number : 8400082

Boca Raton, Florida, United States

Frieder Dermatology- Site Number : 8400085

Boca Raton, Florida, United States

Key Dates

Start Date

August 15, 2019

Primary Completion Date

July 23, 2035

Completion Date

July 23, 2035

Last Updated

August 15, 2025

Enrollment

1,860

ACTUAL participants

Conditions

Dermatitis Atopic

Interventions

Standard of care

OTHER

Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

NCT05769777

Dermatitis Atopic

View study

ACTIVE_NOT_RECRUITING

Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD)

NCT03992417

Dermatitis Atopic

View study

ACTIVE_NOT_RECRUITINGPHASE4

A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 15, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions